Article
Oncology
Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Summary: This study assessed the association between event-free survival (EFS) and overall survival (OS) in the treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. The results showed that EFS is a good surrogate for OS in this setting. Sensitivity analyses confirmed the findings.
CLINICAL CANCER RESEARCH
(2023)
Article
Genetics & Heredity
Carlos A. Barron-Gallardo, Mariel Garcia-Chagollan, Andres J. Moran-Mendoza, Raul Delgadillo-Cristerna, Maria G. Martinez-Silva, Maria M. Villasenor-Garcia, Adriana Aguilar-Lemarroy, Luis F. Jave-Suarez
Summary: Breast cancer is the leading cause of death and incidence among women worldwide, and the HER2+ subtype is known for its aggressiveness. This study aimed to identify prognostic markers for treatment and survival in HER2+ patients. Through RNA-seq analysis, 94 differentially expressed genes related to treatment resistance were identified. Survival analysis revealed that 12 genes were good predictors of disease-free survival, while 8 genes were good predictors of overall survival.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Alina Desiree Sando, Reidun Fougner, Elin Synnove Royset, Hong Yan Dai, Jon Erik Gronbech, Erling Audun Bringeland
Summary: Evaluation of response following neoadjuvant chemotherapy (NAC) in gastric cancer has been widely debated. The aim of this study was to investigate downsizing and downstaging as methods of response evaluation. The findings suggest that comparing the baseline radiological CT stage to the pathological stage following NAC is a useful method for stratifying patients based on their long-term survival rates.
Article
Medicine, General & Internal
Jian-Xian Lin, Yi-Hui Tang, Guan-Jie Lin, Yu-Bin Ma, Jacopo Desiderio, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Chao-Hui Zheng, Amilcare Parisi, Mark J. Truty, Chang-Ming Huang
Summary: This cohort study compares the survival rates of patients with locally advanced gastric cancer who received adjuvant chemotherapy (AC) and those who did not after neoadjuvant chemotherapy followed by surgery. The study found that AC was associated with improved survival in patients with a lymph node ratio of at least 9%. These findings suggest that the lymph node ratio could be useful in AC selection for locally advanced gastric cancer in future decision-making processes.
Article
Oncology
Adrienne B. Shannon, Richard J. Straker, Luke Keele, Douglas L. Fraker, Robert E. Roses, John T. Miura, Giorgos C. Karakousis
Summary: The study found that in patients with gastric adenocarcinoma receiving neoadjuvant chemotherapy, retrieving at least 23 nodes during gastrectomy may improve the 5-year overall survival rate. Therefore, it is important to maintain adequate lymph node retrieval postoperatively for better prognostic prediction.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Pooja Prasad, Ashwin Sivaharan, Maziar Navidi, Bridget H. Fergie, S. Michael Griffin, Alexander W. Phillips
Summary: This study aimed to investigate the impact of neoadjuvant chemotherapy on the prognosis of patients with gastric adenocarcinoma. The results showed that the extent of pathological downstaging in patients who received neoadjuvant chemotherapy was associated with overall survival, and a downstaging of more than 3 stages was the strongest independent predictor of overall survival. Therefore, patients downstaged due to neoadjuvant chemotherapy may have better clinical outcomes.
Article
Oncology
Irene Tizianel, Mario Caccese, Francesca Torresan, Giuseppe Lombardi, Laura Evangelista, Filippo Crimi, Matteo Sepulcri, Maurizio Iacobone, Marta Padovan, Francesca Galuppini, Vittorina Zagonel, Carla Scaroni, Filippo Ceccato
Summary: The study found a significant improvement in survival rates for ACC patients after multidisciplinary team evaluation in 2013. Therefore, it is suggested that ACC patients should be referred to a tertiary center from the time of diagnosis in order to promptly apply all available treatments.
Article
Multidisciplinary Sciences
Bernadette A. M. Heemskerk-Gerritsen, Antoinette Hollestelle, Christi J. van Asperen, Irma van den Beek, Willemien J. van Driel, Klaartje van Engelen, Encarna B. Gomez Garcia, Joanne A. de Hullu, Marco J. Koudijs, Marian J. E. Mourits, Maartje J. Hooning, Ingrid A. Boere
Summary: Germline BRCA1 and BRCA2 pathogenic variant carriers of epithelial ovarian cancer showed survival benefits after chemotherapy, indicating a higher sensitivity to treatment. However, these benefits were limited to a relatively short period after the diagnosis of epithelial ovarian cancer.
Article
Oncology
Kammy Keywani, Alexander B. J. Borgstein, Wietse J. Eshuis, Marieke Pape, Kathelijn S. Versteeg, Sarah Derks, Hanneke W. M. van Laarhoven, Suzanne S. Gisbertz, Rob H. A. Verhoeven, Mark van Berge I. Henegouwen
Summary: The generalizability of perioperative chemotherapy trials for gastric cancer to older patients is uncertain. This retrospective cohort study compared the survival outcomes of patients >= 75 years with gastric adenocarcinoma treated with or without neoadjuvant chemotherapy. The overall survival was not significantly different between patients >= 75 years treated with or without neoadjuvant chemotherapy, but a higher proportion of patients >= 75 years did not proceed to surgery following neoadjuvant chemotherapy compared to younger patients.
Review
Medicine, Research & Experimental
Nicolae Bacalbasa, Camelia Diaconu, Bogdan Socea, Florentina Gherghiceanu, Cornel Savu, Mihai Dimitriu, Irina Balescu, Ioan Cordos
Summary: For advanced-stage gastric cancer, preoperative treatments such as laparoscopic heated intraperitoneal chemotherapy, perioperative heated intraperitoneal chemotherapy, and neoadjuvant systemic and peritoneal chemotherapy are key in improving survival rates and prolonging lifespan for patients.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nickolas Stabellini, Apoorva Krishna Chandar, Amitabh Chak, Amie J. Barda, Mantas Dmukauskas, Kristin Waite, Jill S. Barnholtz-Sloan
Summary: Esophageal cancer is the seventh most common type of cancer worldwide and the sixth leading cause of cancer-related death. The incidence of esophageal cancer is higher in males, but there is limited data on prognosis and survival. This study aimed to analyze the differences between sexes and other factors in patients with primary esophageal cancer. The analysis of data from 2005 to 2020 showed differences between males and females in age at diagnosis, histology, smoking status, and prescriptions of NSAIDs. However, there was no significant difference in survival between males and females.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Hua Liu, Yakun Wang, Changsong Qi, Tong Xie, Zhi Peng, Jian Li, Lin Shen, Xiaotian Zhang
Summary: This study suggests that event-free survival (EFS) could be a surrogate endpoint for neoadjuvant randomized controlled trials (RCTs) of gastric or gastroesophageal adenocarcinoma patients (GC or GEJ ADK). There is a strong correlation between EFS and overall survival (OS) at the trial level.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Dan Moldoveanu, Tanya L. Hoskin, Courtney N. Day, Amy K. Schulze, Matthew P. Goetz, Judy C. Boughey
Summary: This study aimed to evaluate the effectiveness of neoadjuvant chemotherapy in treating node-positive ER+/HER2- breast cancer. The results showed a high rate of pathological complete response in the lymph nodes, which was associated with patient age and Ki67 levels. Pathological complete response in the lymph nodes was positively correlated with overall survival.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Letter
Oncology
Zhonglin Hao, Quan Chen, Bin Huang
Summary: This letter responds to concerns raised by Su et al regarding immortal time bias, which may explain some of the findings in a recently published study.
Article
Oncology
Yonghe Chen, Jiasheng He, Dan Liu, Jian Xiao, Xijie Chen, Haijie Tang, Dandong Luo, Chenyu Shang, Lei Lian, Junsheng Peng
Summary: The study found that in patients with locally advanced gastric cancer, there was no significant difference in efficacy between doublet and triplet neoadjuvant chemotherapy regimens in terms of tumor regression, resection rate, and survival. However, the triplet regimen may increase the risk of post-surgery complications, particularly abdominal infections.